P-096 - (Poster #96) Investigating the Potential Role of MK-677 in Chronic Pain Modulation

With the elderly population growing in number, much medical literature has begun to focus on improving quality of life and mitigating or preventing the effects of physiological aging in certain vulnerable populations. An abundance of existing literature has investigated the effects of both growth hormone-stimulating peptides and cholesterol-derived anabolic hormones on body composition. While naturally occurring hormones are generally well studied, the possibility of undesired effects has prompted the use of drugs of a similar nature that carry a lesser side effect burden.

Ibutamoren, otherwise known as MK-677, is an orally active non-peptide GH secretagogue and ghrelin mimetic that possesses the ability to enhance pulsatile GH secretion and insulin-like growth factor-1 (IGF-1) when used orally. Ghrelin and its receptors are involved in a wide range of physiological processes including energy homeostasis, inflammation, and neuroendocrine function. Notably, ghrelin receptors are expressed in pain perceptive regions of the central nervous system and have been shown to modulate nociceptive processing. Effects of MK-677 include preservation of muscular mass and strength, bone density, physical functionality, and improvements in activities of daily living, all of which are relevant in populations experiencing chronic pain.

Purpose/Objectives:

The anti-inflammatory and neuromodulatory properties of ghrelin signaling may help reduce central sensitization, a key feature in the development and persistence of chronic pain. These effects suggest that MK-677 may offer benefit in chronic pain states by targeting underlying mechanisms that contribute to the amplification of pain signals. The aim of this review is to highlight MK-677’s established effects on improving muscle strength, bone turnover, and physical functioning, as it may serve as a beneficial intervention in populations affected by chronic musculoskeletal conditions or post-injury recovery. Moreover, its non-opioid mechanism of action provides a valuable opportunity to explore opioid-sparing strategies, particularly in elderly or medically complex patients where opioid use may pose greater risks.

Methods:

A literature review was performed and specific inclusion and exclusion criteria were established. Articles were searched using the keywords “Ibutamoren,” “MK-677,” “body mass,” “ghrelin,” “nociception,” “chronic pain,” and “body composition.” Only clinical trials on human subjects, written in the English language, which contained at least MK-677 as a medical intervention were included. A total of 38 prospective studies were produced by the search function. After employing our criteria, a total of 16 studies qualified for our review. These studies were analyzed for evidence of MK-677’s impact on functional outcomes, inflammatory markers, pain-related quality of life, and safety in populations at risk for chronic pain, particularly elderly individuals, those recovering from injury, and patients with cachexia or frailty.

Results:

Although MK-677 has not yet been directly studied for pain relief, existing research in populations with high chronic pain burden offers valuable insight into its therapeutic potential. Two placebo-controlled trials examined MK-677 in elderly patients recovering from hip fractures, a group commonly affected by long-term musculoskeletal pain, disability, and opioid use. These studies contribute important evidence regarding MK-677’s influence on physical function and systemic factors related to recovery and inflammation. These studies observed increases in IGF-1 levels, along with improvements in tasks such as chair rising, stair climbing, and gait speed among their patient cohort, suggesting meaningful support for physical rehabilitation. Despite these notable benefits, MK-677 was documented to have some adverse effects, particularly edema and elevated blood pressure among the patient group. Despite modest functional improvements, the safety profile highlights the need for careful consideration when using MK-677 in this population.

Beyond post-fracture recovery, MK-677 has demonstrated favorable effects on body composition, including increases in lean muscle mass and physical performance. These benefits are particularly relevant for individuals with cancer, cachexia, or age-related frailty, who often experience chronic pain and mobility limitations. By promoting muscle strength, mobility, and reducing inflammation, MK-677 may help ease pain-related disability and improve overall quality of life. These findings support MK-677’s role as a promising adjunctive therapy for enhancing musculoskeletal health in high-need populations. Additionally, MK-677’s non-opioid mechanism of action makes it a compelling candidate for opioid-sparing approaches. Supporting function and reducing inflammation without targeting opioid receptors may lessen reliance on traditional analgesics while promoting greater autonomy and recovery.

Conclusions/Implications for future research and/or clinical care:

It appears that MK-677 may be a well-tolerated modality among elderly populations, as MK-677 possesses anti-catabolic properties and seemingly improves markers of bone turnover. Most notably, MK-677’s effects are not mediated through the opioid system, making it a potential candidate for opioid-sparing strategies for patients experiencing pain. This is especially relevant in the current climate of opioid misuse and overuse, where the need for effective non-opioid alternatives in chronic pain management is critical. By reducing central sensitization and improving function through neuromodulatory and anti-inflammatory pathways, MK-677 presents an opportunity to shift the approach in chronic pain management. 

Despite all these prodigious benefits, there is some uncertainty in the safety profile of MK-677, especially in older populations with comorbidities. Further careful investigation may be warranted to determine whether the risk-benefit ratio of MK-677 can be justified to treat chronic musculoskeletal or inflammatory pain-related conditions. Further research into MK-677’s role in reducing pain, improving function, and minimizing opioid use is strongly encouraged. Establishing its clinical efficacy and safety could offer a valuable alternative in the evolving landscape of chronic pain management.